more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Ironwood Suffer From Dependence on Linzess' Progress?

by Zacks Equity Research Published on April 05,2019

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

pharmaceuticals

Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

by Kinjel Shah Published on April 05,2019

Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

pharmaceuticals

Editas (EDIT) Inks Cross Licensing Agreement with BlueRock

by Zacks Equity Research Published on April 04,2019

Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.

biotechs

Allergan's AMD Drug Lowers Inflammation in Phase III Study

by Zacks Equity Research Published on April 03,2019

Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

pharmaceuticals

Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research Published on April 02,2019

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AGNPositive Net Change

Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics

by Zacks Equity Research Published on April 01,2019

Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.

pharmaceuticals

Spero Gets Fast Track Designation for SPR994, Shares Improve

by Zacks Equity Research Published on April 01,2019

Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.

biotechs

NASH Scorecard So Far This Year: A Look at the Hits & Misses

by Ekta Bagri Published on March 29,2019

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

Axsome's Depression Drug Gets Breakthrough Therapy Status

by Zacks Equity Research Published on March 28,2019

Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).

pharmaceuticals

Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?

by Zacks Equity Research Published on March 28,2019

Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.

Company News For Mar 26, 2019

by Zacks Equity Research Published on March 26,2019

Companies In The News Are: BA, AGN, NKE, VIAB, T

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

by Zacks Equity Research Published on March 21,2019

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

medical

NASH, Allergies and Beauty Stocks: Invest or Not?

by Tracey Ryniec Published on March 20,2019

There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

by Zacks Equity Research Published on March 20,2019

Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

medical

Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients

by Zacks Equity Research Published on March 19,2019

The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

pharmaceuticals

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

by Zacks Equity Research Published on March 18,2019

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

pharmaceuticals

Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

by Zacks Equity Research Published on March 15,2019

Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

pharmaceuticals

Allergan Announces FDA Acceptance of Migraine Candidate NDA

by Zacks Equity Research Published on March 12,2019

Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.